ALDA to Request Human Trials for Athlete's Foot With New T36(R) Anti-Inflammatory, Anti-Microbial Therapeutic

09:00 EST Tuesday, May 13,

2008VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 13, 2008) -

ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") announces that it has received positive results from BioScience Laboratories, Inc. for the T36(R) formulation which was tested against two species of fungi responsible for athlete's foot, Trichophyton mentagrophytes and Trichophyton rubrum. T36(R) achieved a complete kill of both organisms within 5 minutes, the shortest time required by the FDA.

Completion of these tests allows ALDA to approach Health Canada with a Clinical Trial Application ("CTA") for testing of the new T36(R) anti-inflammatory, anti-microbial formulation against athlete's foot. Once the CTA has been approved by Health Canada, human trials can begin.

ALDA can now also request a "pre-IND" (pre-Investigational New Drug) meeting with the FDA for human tests of the new T36(R) formulation against athlete's foot. From this meeting, any additional tests required by the FDA before human trials can begin will be clarified.

Dr. Terrance Owen, President & CEO, states, "The new T36(R) anti-inflammatory anti-microbial formulation is an important new product in our arsenal of infection control therapeutics. As announced in a news release dated March 25, 2008, this new product has already been successfully tested against a number of topical infections, including athlete's foot, diaper rash and eczema and we have filed a PCT patent application. Athlete's foot is an ideal indication to pursue initially since it is relatively easy to test, represents a large market and will allow physicians to prescribe the product 'off-label' for other topical infections once it has been approved. We are very excited by the prospect that we are now able to request human trials and we are starting the preparation of the protocols immediately.

"About ALDA Pharmaceuticals Corp.ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.Terrance G. Owen, Ph.D., MBAPresident, CEO and Director